Polyrizon Ltd. announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker. The study, conducted on fully differentiated human nasal tissue using the MucilAir™ model, demonstrated strong local tolerability.
The study assessed local tolerance and tissue response following a 4-hour application of PL-14, a mucoadhesive nasal gel spray designed to act as a physical barrier against airborne allergens. Key safety indicators, including tissue integrity, cytotoxicity, cilia beating frequency, mucociliary clearance, and inflammatory response, were evaluated.
Results showed that tissue viability and function remained consistent with baseline and vehicle controls, with no signs of inflammatory activation or functional impairment. These findings represent an important milestone in validating the local safety of PL-14 and provide foundational support for advancing clinical development and the upcoming FDA pre-submission meeting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.